BACKGROUND: @entity1124 ( @entity1124 ) has a very poor prognosis. Treatment with FOLFIRINOX has been shown to improve outcomes, but can be associated with significant @entity137 . MATERIALS AND METHODS: A  retrospective review was performed of all @entity1 with locally advanced or metastatic @entity1124 treated with FOLFIRINOX at the Royal Marsden between November 2010 and November 2013. Efficacy, tolerability, and potential prognostic factors were evaluated. RESULTS: Twenty-seven @entity1 with metastatic @entity1124 and 22 @entity1 with locally advanced @entity1124 were treated with FOLFIRINOX. @entity1 received a median of 9 cycles (range, 1-26) of FOLFIRINOX. The overall response rate was 41% (20 @entity1 ), and a further 17 @entity1 (35%) had stable disease. Thirty-five @entity1 (71%) received FOLFIRINOX in the first-line setting, with a median progression-free survival and overall survival, respectively, of 12.9 months and 18.4 months for @entity1 with locally advanced disease; and 8.4 months and 12.2 months for @entity1 with @entity3 . The most frequently occurring Grade 3/4 @entity137 were @entity1398 (29%), @entity1295 (18%), @entity1398 (14%), @entity1031 (12%), and @entity882 (10%). In a univariate analysis, reduction in CA 19-9 of >50% (P  < .001), normalization of CA19-9 (P  < .001), surgery after FOLFIRINOX (P  =  .004), and use of prophylactic pegfilgrastim (P  = .005) were prognostic for overall survival. CONCLUSION: The efficacy and tolerability of FOLFIRINOX for @entity1124 at our institution is similar to that reported in clinical trials. Careful selection of @entity1 and monitoring of response (according to CA19-9) and @entity137 can help maximize advantage in this @entity1 population.

FOLFIRINOX for Locally Advanced or Metastatic XXXX : The Royal Marsden Experience.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity1124 :: ('MESH:D021441', 'Disease') :: ['Pancreatic ductal adenocarcinoma', 'PDA'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']
@entity1124 :: (MESH:D021441,Disease) :: ['Pancreatic Ductal Adenocarcinoma']
